Clene Inc
CLNN
Company Profile
Business description
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Contact
6550 South Millrock Drive
Suite G50
Salt Lake CityUT84121
USAT: +1 801 676-9695
Sector
Consumer Defensive
Stock type
Defensive
Industry
Packaged Foods
Fiscal Year End
31 December 2026
Employees
79
Stocks News & Analysis
stocks
Higher credit stress for big four bank
Shares fall after announcement that capital will be replenished for loan impairment provisions.
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,162.20 | 31.00 | -0.34% |
| CAC 40 | 8,331.05 | 94.08 | -1.12% |
| DAX 40 | 24,417.80 | 284.44 | -1.15% |
| Dow JONES (US) | 49,442.56 | 4.87 | -0.01% |
| FTSE 100 | 10,609.08 | 58.55 | -0.55% |
| HKSE | 26,458.44 | 97.37 | 0.37% |
| NASDAQ | 24,404.39 | 64.09 | -0.26% |
| Nikkei 225 | 59,506.89 | 1,030.99 | 1.76% |
| NZX 50 Index | 12,927.16 | 21.49 | 0.17% |
| S&P 500 | 7,109.14 | 16.92 | -0.24% |
| S&P/ASX 200 | 8,935.10 | 34.40 | -0.38% |
| SSE Composite Index | 4,080.01 | 2.12 | -0.05% |